Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency
摘要:
In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency
摘要:
In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.
Azaquinazoline Inhibitors Of Atypical Protein Kinase C
申请人:Ignyta, Inc.
公开号:US20150274720A1
公开(公告)日:2015-10-01
The present application provides a compound of formula (I)
and/or a salt thereof, wherein R
1
, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.
IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20150210703A1
公开(公告)日:2015-07-30
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Azaquinazoline inhibitors of atypical protein kinase C
申请人:CANCER RESEARCH TECHNOLOGY LIMITED
公开号:US10414763B2
公开(公告)日:2019-09-17
The present application provides a compound of formula (I)
and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
本申请提供了一种式 (I) 的化合物
和/或其盐,其中 R1、G 和 X 如本文所定义。式(I)化合物和/或其盐具有 PKC 抑制活性,可用于治疗增殖性疾病。还提供了包含式(I)化合物和/或其盐的组合物。